U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H44O9
Molecular Weight 548.665
Optical Activity UNSPECIFIED
Defined Stereocenters 13 / 13
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERUVOSIDE

SMILES

[H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@H](CC[C@]34O)C5=CC(=O)OC5)[C@]1(CC[C@@H](C2)O[C@]6([H])O[C@@H](C)[C@H](O)[C@@H](OC)[C@@H]6O)C=O

InChI

InChIKey=PMTSPAGBAFCORP-HBUONDEYSA-N
InChI=1S/C30H44O9/c1-16-24(33)26(36-3)25(34)27(38-16)39-19-6-10-29(15-31)18(13-19)4-5-22-21(29)7-9-28(2)20(8-11-30(22,28)35)17-12-23(32)37-14-17/h12,15-16,18-22,24-27,33-35H,4-11,13-14H2,1-3H3/t16-,18+,19-,20+,21-,22+,24-,25-,26+,27-,28+,29+,30-/m0/s1

HIDE SMILES / InChI

Molecular Formula C30H44O9
Molecular Weight 548.665
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 13 / 13
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Peruvoside, main component of neriperside, a tevetoside extracted from Thevitia neriifolia Juss, cardiac glycoside, is used for the treatment of heart failure. It is Na+, K(+)-ATPase inhibitor. Peruvoside also demonstrates anti-cancer activities. Peruvoside inhibited cell growth in androgen-resistant LNCaP-abl prostate at 50 nM, lower than the concentrations required by both Digoxin and Strophanthidin (500 nM), suggesting that it may be a more potent anti-cancer candidate that other CGs. Peruvoside induced apoptotic cell death in human primitive AML KG1a cells and chronic myelogenous leukemia (CML) cell K562.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
75.0 µM [IC50]
0.18 µM [IC50]
45.0 nM [IC50]
10.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Encordin
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Congattve Heart Failure :The average effective dose was 2.4 mg. (1.8 to 3.2 mg.) followed by a maintenance dose of 0.6 mg (0.3 to 0.9 mg.).
Route of Administration: Intra-arterial
In Vitro Use Guide
Peruvoside inhibited cell growth in androgen-resistant LNCaP-abl prostate at 50 nM
Substance Class Chemical
Record UNII
CT36KGC6A6
Record Status Validated (UNII)
Record Version